KEMPOWER
Kemppi Group Oy, the owner of Kempower Oy, acquires a business property managed by S-Bank Properties, including 10 300 m2 of factory space. The new facility will enable Kempower to scale up production by approximately 500% compared to its current capacity. Kempower will gradually ramp up production in 2021-2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005423/en/
Kempower, a leading e-mobility charging technology provider in the Nordics, responds to the rapidly growing e-mobility market demand by scaling up production gradually by the end of 2022. Kemppi Group Oy, the owner of Kempower Oy, acquires a business property including 10 300 m2 of factory space. The business property includes extensive unused building right to further expand production in the future. The seller in the transaction is the insurance group Fennia, for which S-Bank's subsidiary S-Bank Properties Ltd provides real estate portfolio management and administration services.
The factory, originally built in 2007 and expanded in 2020, is located in Rälssinkatu 1, Lahti, Finland, with excellent transport connections. Kemppi Group will lease the factory to Kempower. The new facility will enable Kempower to expand its production by approximately 500% compared to the current capacity. Kempower’s production will be scaled up for the second time in a short time: at the beginning of 2021, Kempower increased its production by five times from the 2020 level.
“As Kempower’s owners, we are very committed to the company. Kempower has a lot of growth potential and the international EV charging market has reacted positively to Kempower’s DC charging offering. With this investment, we want to ensure Kempower’s ability to respond to the market demand”, states Antti Kemppi , Chairman of the Board of Kemppi Group & Kempower.
”We are particularly pleased to be able to continue the life of this valuable business property and to provide new jobs in the Lahti region”, Antti Kemppi adds.
“It’s great that this well-kept property found a new home. I believe that the site's modern production facilities offer a great platform to develop business in the future” says Harri Oravainen , Real Estate Investment Director, S-Bank Properties.
“Our aim is to be the preferred partner in the world in developing emission-free business. Our ultimate goal is to create an EV charging infrastructure so extensive and reliable, that the electric vehicles can and will be the new reality. With the new facility, we are able to support our customers in developing emission-free business even faster than before”, states Tomi Ristimäki , CEO, Kempower.
“In the new facility, Kempower will have all the essential functions in one location, including production, R&D, laboratory, testing and offices. The new facility will allow us to be efficient and agile as all the teams will be working seamlessly under one roof”, says Tomi Ristimäki , CEO, Kempower.
The preparations for Kempower’s new facility will start immediately. To ensure customer deliveries, Kempower will gradually ramp up production in 2021-2022. All company functions will be moved to the new location by the end of 2022.
Catella Asset Management acted as Kemppi Groups’ buyside advisor and HPP Attorneys as legal advisors on the transaction.
Kempower designs and manufactures DC fast charging solutions for electric vehicles and machines operating in the most demanding conditions. We are a largescale charging system supplier, aiming for a smoothly running electric mobility infrastructure. With 70 years of experience in perfecting power sources, we set the bar high in engineering and user-experience design. Over 90% of our materials & components are sourced from Finland. Kempower DC charging solutions are designed and manufactured in Lahti, Finland, and available globally. www.kempower.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005423/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom